EpiVacCorona vaccine

chemically synthesized peptide antigens of SARS-CoV-2 proteins conjugated to a carrier protein and adsorbed on aluminum hydroxide

Also Known As:

Aurora-CoV; EpiVacCorona; EpiVacCorona COVID-19 vaccine; EpiVacCorona-N

Networked: 4 relevant articles (1 outcomes, 1 trials/studies)

1.	COVID-19 05/18/2023 - "Assessment of Safety and Prophylactic Efficacy of the EpiVacCorona Peptide Vaccine for COVID-19 Prevention (Phase III)." 06/21/2022 - "The goal of this study was to evaluate the epidemiological effectiveness of the Sputnik V and EpiVacCorona vaccines against COVID-19. " 06/21/2022 - "According to our analysis, EpiVacCorona proved to be an ineffective vaccine and therefore cannot protect against COVID-19." 01/01/2022 - "In the primary analysis, we used logistic regression models to estimate the adjusted (age, sex, and history of confirmed COVID-19) VE against symptomatic SARS-CoV-2 resulted in a referral to triage centre for three vaccines used in Russia: Gam-COVID-Vac, EpiVacCorona, and CoviVac. "
2.	Lung Injury 10/10/2022 - "VE estimates against severe lung injury were 76% (67-82) for two-dose Gam-COVID-Vac (Sputnik V), 87% (76-93) for three-dose Gam-COVID-Vac, 36% (-63 to 75) for EpiVacCorona, and 80% (45-92) for CoviVac. " 10/10/2022 - "The adjusted for age, sex and triage centre VE estimates against any lung injury were 56% (95% confidence interval 54-59) for two-dose Gam-COVID-Vac (Sputnik V), 71% (68-74) for three-dose Gam-COVID-Vac (booster), 2% (-27 to 24) for EpiVacCorona, and 46% (37-53) for CoviVac. " 10/10/2022 - "Gam-COVID-Vac, EpiVacCorona, and CoviVac effectiveness against lung injury during Delta and Omicron variant surges in St. Petersburg, Russia: a test-negative case-control study."